Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05607420 · ClinicalTrials.gov registry record · Phase 1

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

A Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Cellectis S.A..

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
10
Study locations

NCT05607420 is a Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL) that is actively recruiting participants, run by Cellectis S.A.. The registered enrollment target is 80 participants, below the 215-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (63% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05607420, a Phase 1 study of B-cell Non-Hodgkin Lymphoma (B-NHL), is actively recruiting participants, sponsored by Cellectis S.A..

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
10
Study locations

Study Summary

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

Conditions Studied

B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

  • BIOLOGICAL CLLS52
  • BIOLOGICAL UCART20x22

Study Locations (10)

Other

  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu - Nantes
  • Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS) - Seville

Illinois

  • The University of Chicago Medical Center (UCMC) - Chicago

Massachusetts

  • Harvard Medical School - Massachusetts General Hospital - Boston

New Jersey

  • Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick - New Brunswick

Texas

  • Sarah Cannon - St. David South Austin Medical Center - Austin

Auvergne Rhone Alpe

  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud - Pierre-Bénite

Occitanie

  • Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi - Montpellier

Île-de-France Region

  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie - Paris

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2022-11-01
Est. Completion 2027-08
Phase Phase 1

Sponsor

Cellectis S.A.

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05607420

The ClinicalTrials.gov registry entry for NCT05607420 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (63% lower). The listed sponsor is Cellectis S.A., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B-cell Non-Hodgkin Lymphoma (B-NHL) appearing as the primary indexed condition, and to 2 interventions - of which CLLS52 is the first listed.

NCT05607420 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05607420 about?

NCT05607420 is a clinical study titled "Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma". First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum To...

What is the current status of trial NCT05607420?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2022-11-01. Estimated completion is 2027-08.

What conditions does trial NCT05607420 study?

This clinical trial studies the following conditions: B-cell Non-Hodgkin Lymphoma (B-NHL).

What interventions are being tested in trial NCT05607420?

The interventions under investigation include: CLLS52 (BIOLOGICAL), UCART20x22 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05607420?

This trial is sponsored by Cellectis S.A., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05607420 being conducted?

This trial has 10 study locations across Illinois, Massachusetts, New Jersey, Texas, Auvergne Rhone Alpe. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Non-Hodgkin Lymphoma (B-NHL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-cell Non-Hodgkin Lymphoma (B-NHL)

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.